Salem Investment Counselors’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.9K Hold
145
– – ﹤0.01% 694
2026
Q1
$25K Buy
+145
New +$26.9K ﹤0.01% 709
2025
Q4
– Sell
-145
Closed -$22.7K – 551
2025
Q3
$22.7K Hold
145
– – ﹤0.01% 723
2025
Q2
$22K Hold
145
– – ﹤0.01% 702
2025
Q1
$21.8K Hold
145
– – ﹤0.01% 700
2024
Q4
$26.8K Hold
145
– – ﹤0.01% 687
2024
Q3
$28.6K Hold
145
– – ﹤0.01% 687
2024
Q2
$30K Hold
145
– – ﹤0.01% 663
2024
Q1
$39.3K Hold
145
– – ﹤0.01% 600
2023
Q4
$34.3K Hold
145
– – ﹤0.01% 615
2023
Q3
$28.4K Hold
145
– – ﹤0.01% 624
2023
Q2
$30.5K Hold
145
– – ﹤0.01% 618
2023
Q1
$29.3K Hold
145
– – ﹤0.01% 630
2022
Q4
$31.6K Hold
145
– – ﹤0.01% 590
2022
Q3
$29K Sell
145
-95
-40% -$20.5K ﹤0.01% 571
2022
Q2
$51K Buy
240
+95
+66% +$23.2K ﹤0.01% 500
2022
Q1
$41K Hold
145
– – ﹤0.01% 538
2021
Q4
$55K Hold
145
– – ﹤0.01% 546
2021
Q3
$60K Hold
145
– – ﹤0.01% 478
2021
Q2
$54K Hold
145
– – ﹤0.01% 474
2021
Q1
$42K Buy
145
+135
+1,350% +$37.5K ﹤0.01% 473
2020
Q4
$2K Buy
+10
New +$2.38K ﹤0.01% 753

Other funds holding CRL

Salem Investment Counselors's CRL Position: Q2 2026 in Review

Salem Investment Counselors held its Charles River Laboratories (CRL) position steady in Q2 2026 at 145 shares worth $32.9K. The position accounts for ﹤0.01% of the portfolio, ranked #694.

Salem Investment Counselors first reported a position in CRL in Q4 2020 and has held it in 22 quarters since. The position peaked at $60K in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Salem Investment Counselors held 145 shares of Charles River Laboratories worth $32.9K as of Q2 2026.
  • Salem Investment Counselors left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #694 holding.
  • Salem Investment Counselors first reported a position in Charles River Laboratories in Q4 2020 and has held it in 22 quarters since.
  • Salem Investment Counselors's Charles River Laboratories position peaked at $60K in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.